Patients Using ROX-888 Required Significantly Less Morphine After Major Abdominal Surgery Company On Track To File NDA In 2008

MENLO PARK, CA (June 6, 2007) – ROXRO PHARMA Inc. said today that ROX-888, its novel intranasal analgesic, rapidly and effectively eased pain and was well tolerated by patients who had undergone major abdominal surgery in a Phase 3 clinical study.

"This completes our second and final Phase 3 clinical study," said ROXRO PHARMA’s Chief Scientific Officer Roger Whiting. The company intends to include fully analyzed data in its New Drug Application for submission to the U.S. Food and Drug Administration. "We are very pleased with the solid results of this Phase 3 study and are on track to file our NDA in the first half of 2008," Whiting said.

In the Phase 3 study, patients who received ROX-888 reported greater improvement in pain relief and required 22 percent less morphine in the first 24 hours following surgery compared to patients who had access to morphine alone. ROX-888 is an intranasal formulation of ketorolac, a non-steroidal anti-inflammatory medicine most often administered as an intramuscular injection or intravenously for the short-term treatment of moderately severe pain. "ROX-888 is an important breakthrough in treating pain," said Dr. Neil Singla, Director of Clinical Research at Huntington Memorial Hospital in Los Angeles. "It is rapidly absorbed into the bloodstream, and relieves pain as fast as an intramuscular injection. There is a need for new analgesics like ROX-888 that do not have the troublesome side effects and abuse risks associated with narcotic pain relievers." The Phase 3 double-blind, placebo-controlled study included 321 patients who had undergone major abdominal surgery. Patients were randomized to receive either intranasal ketorolac (30 mg) or placebo. All study participants had access to patient-controlled morphine. "Pain is at its greatest intensity in the first 24
'"/>




Page: 1 2
Related medicine technology :

1. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
2. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
3. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
4. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
7. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
8. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
9. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
10. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
11. VGX Pharmaceuticals Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models